# Measurement of Hepatocyte Growth Factor, Interleukin 6 and Tumor necrosis factor $\alpha$ in Acute Myocardial Infarction

## Asadallah Keshmiri<sup>1</sup>, Ali Reza Derakhshan<sup>2</sup>, Afsoon Fazlinejad<sup>3</sup>, Reza Farid-Hosseini<sup>4</sup>

<sup>1</sup> Department of Emergency Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran. asad.keshmiri@yahoo.com

<sup>3</sup> Echocardiography Research fellow, Mayo clinic 13400 E Shea Blvd, Arizona. Fazlinezhad.afsoon@mayo.edu

<sup>4</sup> Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. rfarid@gmail.com

*Corresponding Author:* Afsoon Fazlinejad Echocardiography Research fellow, Mayo clinic *Address:* 13400 E Shea Blvd, Arizona. *E-mail:* Fazlinezhad.afsoon@mayo.edu

*Cite this article as:* Keshmiri A, Derakhshan AR, Fazlinejad A, et al. Measurement of Hepatocyte Growth Factor, Interleukin 6 and Tumor necrosis factor α in Acute Myocardial Infarction. Nepalese Heart Journal 2019; Vol 16(1), 33-37

*Received date:* 11th October 2018 *Accepted date:* 30th March 2019

#### Abstract

**Background:** Early mortality rate due to acute myocardial infarction (AMI) is approximately 30%, and half of these deaths occur before reaching a hospital. The prevention and early detection play a key role in reducing mortality in AMI. Hepatocyte Growth Factor (HGF), Interleukin 6 (IL-6), and Tumor Necrosis Factor  $\alpha$  (TNF- $\alpha$ ) are most recent prognostic biomarkers for AMI. The present study was aimed to evaluate the level of these cytokines in AMI.

**Methods:** In this case control study, 39 patients with AMI were compared with 30 healthy subjects. Age, sex and other possible confounding factors were matched. AMI diagnosis was confirmed by typical symptoms, electrocardiogram changes and serum concentration of troponin I and creatine kinase-MB. The levels of  $TNF-\alpha$ , IL-6 an HGF at baseline and 3 and 7 days later were measured using ELISA method.

**Results:** Levels of IL-6, TNF- $\alpha$  and HGF increased over time after AMI with ST-segment elevation in study group. The baseline IL-6 levels in AMI group were significantly higher than control group (P<0.05).

**Conclusions:** The results of this study suggest that baseline levels of IL-6 as well as serial changes of serum IL-6, TNF- $\alpha$  and HGF concentrations can be used as potential diagnostic biomarkers in AMI.

Keywords: acute myocardial infarction, hepatocyte growth factor, interleukin 6, TNF-a

DOI: https://doi.org/10.3126/njh.v16i1.23896

### Introduction

One of the major causes of mortality and morbidity worldwide, especially in many developed countries is coronary artery disease (CAD).<sup>1</sup> In some countries CAD is the cause of nearly half (48%) of the deaths, and as a result loss of the productivity of life. If no serious action is taken, the number of years of productivity life lost to CAD will increase to 64% for Brazil and even more dramatically to 95% for India, by 2030 as compared to 2000.<sup>2</sup> According to the World Health Organization, it is predicted that by 2030, 23.6 million deaths per year will be due to cardiovascular diseases.<sup>1</sup> A large proportion of CADs occur because of the atherosclerosis. Although the etiology of atherosclerosis is complex and poorly known, there is growing evidence that inflammation plays a central role in developing atherosclerotic lesion, which is in turn widely considered to be related to an inflammatory process.<sup>3</sup> It has been proven that both behavioral risk factors (such as tobacco use, unhealthy diet, physical inactivity, and harmful use of alcohol) and metabolic risk factors (such as diabetes, hypertension, high blood lipids, overweight and obesity) possess a crucial role in the etiology of atherosclerosis.<sup>5</sup> The fragility of the atherosclerotic plaque is associated with the inflammation and plays a significant role in destroying of the fibrous cap, which is the main pathophysiological event for the progression of acute coronary syndromes (ACS) such as unstable angina (UA) and acute myocardial infarction (AMI).<sup>6</sup> Recent studies showed that some inflammatory cytokines (IL-6, TNF- $\alpha$  and IL-10) were predictors for cardiovascular outcome.<sup>7,8</sup> During the first 48 hours of an ACS, IL-6 has been proved a great predictor of a major adverse cardiovascular event over the first month after the initial coronary event and the first year.<sup>9</sup> It has been observed

@Nepalese Heart Journal. Nepalese Heart Journal retains copyright and work is simultaneously licensed under Creative Commons Attribution License CC - BY 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.



<sup>&</sup>lt;sup>2</sup> Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad. Iran derakhshanar@mums.ac.ir

that circulating IL-6 concentrations is positively associated with the risk of CAD. Also, high IL-6 levels during acute coronary syndromes (ACS) may be associated with worse long-term prognosis.<sup>10</sup> Some studies have indicated that IL-6 and CRP are powerful predictors of risky coronary events in patients with UA as well as independent risk factors for future MI. In addition, levels of TNF- $\alpha$  were associated with high risk of recurrent coronary events and it is also able to be potential markers for prediction of cardiovascular events.<sup>11-13</sup>

Hepatocyte growth factor (HGF) is a cytokine with multipotent actions.<sup>14</sup> It has multiple activities in various tissues during the development of diverse diseases and regulates cell growth, cell motility, and morphogenesis of various types of cells. HGF is also a sensitive biomarker for early diagnosis of acute myocardial infarction that between the known biomarkers, it rises the earliest and very promptly returns to normal values.<sup>15, 16</sup> Some study showed that HGF levels on admission in patients with AMI were higher than control values and peaked on 7th day.<sup>17, 18</sup> In addition, it has been demonstrated that serum HGF concentrations in early stage might reflect the extent of myocardial damage in AMI patients. HGF was increased within three hours after onset of chest pain in most of AMI patients.<sup>16</sup> Therefore, HGF is useful as a prognostic indicator in patients with AMI and reflects the clinical course of disease.

The aim of this study, is finding cytokine levels and serial changes of HGF, IL-6, and TNF- $\alpha$  in the patients with ST elevation AMI.

#### **Methods and materials**

We conducted a case control hospital-based study on 39 patients with AMI who were referred to the Ghaem academic hospital in Mashhad (northeast of Iran) and 30 healthy control subjects. AMI was diagnosed based on typical chest pain lasting 30min, with ST-T segment elevation>0.2 mV in 2 or more contiguous leads on a standard 12-lead electrocardiogram and an increase in Troponin and Creatine Kinase MB activity that was at least twice the upper limit of normal. Healthy control subjects (n = 30) were recruited from among subjects who were referred to for an annual checkup or pre-employment examination as they were assumed not to have CAD and gave no history of cardiovascular symptoms. Also, patients who had history of antiplatelet and statin medication were excluded from control group.

Case and controls subjects were age, and sex matched Clinical signs and laboratory results (Troponin I and Creatine Kinase MB) of patients with AMI were documented.

The levels of these cytokines were evaluated at three points in the patients with AMI. In addition, the possible relationship between these three factors with echocardiographic findings and Killip class were evaluated. Killip classification is defined based on the Killip's article in 1967.<sup>19</sup>

## The Laboratory Measurement of Cytokines and biochemical parameters

Venous blood samples were taken from patients immediately before the administration of heparin at the time of admission, and 3 and 7 days later. Serums were separated from blood samples by centrifugation, and were stored at -70°C. ELISA cytokines have been used for HGF, IL-6, and TNF-a measurement.

Fasted blood samples (20 ml) were collected into plain Vacutainer<sup>™</sup> tubes, for cytokines and growth factor measurements, lipid profile and those for measurement of fasting blood glucose was taken into Vacutainer<sup>™</sup> tubes containing fluoride-oxalate.<sup>20</sup> Total cholesterol (TC), low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), Triglyceride (TG) and fasting blood sugar (FBS) were measured using routine techniques using a Cobas auto-analyser system (ABX Diagnostics, Montpellier, France).<sup>20</sup>

The results of the FBS<110 mg/dL were interpreted normal values, FBS between 110 and 126 mg/dL were considered as impaired fasting glucose (IFG), and FBS>126 mg/dL were considered as Diabetes Mellitus, according to the American Diabetic Association criteria.<sup>20</sup>

#### **Statistical analysis:**

The Statistical Package for Social Sciences (SPSS version 16) was used for data analysis. The Kolmogorov-Smirnov test was used to assess normality. Descriptive statistics (frequency, mean, and standard deviation) were determined for all variables. Values are reported as mean ±SD for normally distributed variables (or Median and IQR for not normal distribute variable). Baseline demographics and clinical characteristics were compared among groups using t-student test, chi-square test, and/or Fisher exact test as appropriate. A P-value<0.05 was regarded as statistically significant.

#### **Ethical Issue:**

The study was conducted in accordance with the principles of Declaration of Helsinki 1996 version and Good Clinical Practice standards. The study protocol, informed-consent form, and the other study related documents were reviewed and approved by Human Research Ethics Committee of Mashhad University of Medical Sciences.

#### Results

The main age of case group subjects was  $55.74\pm13.08$  and in the control group was  $64.9\pm10.5$  with no significant difference between groups in sex, smoking habit, opium addiction, hypertension, hyperlipidemia, diabetes mellitus, and stroke history (P>0.05) (table1).

In case group 41%(16 subjects) had history of unstable angina whereas in control group nobody had this history and there was a significant difference between groups (P<0.001) (table1).

In the biochemical components of blood analysis there were no significant difference between groups in FBS, LDLC, HDLC, TC, TG, BUN, Creatinine, Hemoglobin, and Hematocrit (P>0.05) (table1).

According to the electrocardiograph analysis most of patients in case group (more than 77%) had inferior wall ST elevation myocardial infarction (MI) followed by anterior wall ST elevation MI (table2).

In cytokine assay between groups at baseline, IL-6 in case group was significantly higher than control group (P=0.001) but differences in HGF and TNF- $\alpha$  are not significant (P>0.05) (table 1). In addition, serial cytokine assay in case group showed that serum levels of IL-6, TNF- $\alpha$  and HGF have increased significantly over time (P<0.05)(table 3). Measurement of Hepatocyte Growth Factor, Interleukin 6, and Tumor necrosis factor  $\alpha$  in Acute Myocardial Infarction

Table 1- ba	asic charact	eristics of cas	se and control	l subjects
-------------	--------------	-----------------	----------------	------------

Ageint int int int int int int int int int	group Variable		Case N=39	Control N=30	P value
<table-row><table-row><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row><table-row><table-container><table-container><table-container><table-container><table-row><table-row><table-row><table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-row></table-row></table-row></table-row></table-row></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-container></table-row></table-row>	Age		55.74±13.08	64.9±10.5	0.477
Female13(3.3)12(40)ImageSmakingPresent12(30)10(3.3.3)0.774Addiction historyPresent7(70)20(6.7)0.611Adjertion historyPresent10(9.8)22(73.4)1HypertensionPresent10(9.8.7)826.6)0.840Diabetes Mellitus0.78120(5.1.3)22(73.4)0.743Diabetes MellitusPresent20(5.1.3)21(73.4)0.743Diabetes MellitusPresent8169.75)27(90,0.743MyperlipidemiaPresent8169.75)20(6.7)0.334Mysent20(3.1.3)10(3.3.3)0.9310.931Stroke HistoryPresent20(1.9.1)20(96.6)0.001Mysent21(9.9.1)10(3.3)0.9010.001Mysent21(9.9.1)10(3.3)0.0100.01Mysent21(9.9.1)10(3.3)0.9010.01Mysent21(9.9.1)10(3.3)0.9010.01Mysent10(4.1)10(3.3)0.9010.01Mysent21(9.1)10(3.3)0.910.01Mysent10(4.1)10(1.9.1)10(1.9.1)0.01Mysent21(9.9.1)10(3.3)0.910.01Mysent12(9.9.1)10(1.9.1)10(1.9.1)10(1.9.1)Mysent10(1.9.1)10(1.9.1)10(1.9.1)10(1.9.1)Mysent10(1.9.1)10(1.9.1)10(1.9.1)10(1.9.1)Mysent10(1.9.1)10(1.9.1) <t< td=""><td>Sex</td><td>Male</td><td>26(66.7)</td><td>18(60)</td><td>0.567</td></t<>	Sex	Male	26(66.7)	18(60)	0.567
Smoking MemberPresent12(30)10(3.3.)0.874Abern27(70,0020(6.7,00)6Addicion historyPresent3(20.1)2(2.3.4)6Hypertension20(3.1,00)2(2.3.4,00)0.840Mater20(5.1,3,00)2(2.3.4,00)0.840Diabetes MellitusPresent0(0.5,3,00)2(7.0,00)0.743MyperlipidemiaPresent3(10,00)0.7430.743MyperlipidemiaPresent3(8.9,7)3(3.3,00)0.844MyperlipidemiaPresent0(2.3,00)0.8430.843MyserlipidemiaPresent2(5.1)1(3.3.3,00)0.953MyserlipidemiaPresent2(5.1)1(3.3.3,00)0.953MyserlipidemiaPresent2(5.1)0(0.0,00)0.001MyserlipidemiaSigence3(70,00)0.0010.001MyserlipidemiaSigence3(70,00)0.0010.001MyserlipidemiaSigence3(20,00)0.0010.001MyserlipidemiaSigence3(20,00)0.0110.011MyserlipidemiaSigence3(20,00)0.0110.011MyserlipidemiaSigence3(20,00)0.0110.011MyserlipidemiaSigence3(20,00)0.0110.011MyserlipidemiaSigence3(20,00)0.0110.011MyserlipidemiaSigence3(20,00)0.0110.011MyserlipidemiaSigence3(20,00)0.0110.011Mys		Female	13(33.3)	12(40)	
Absent27(70)20(60.7)Image (1)Addiction historyPresent7(7.9)8(26.6)0.611Hypertension20(8.1)2(7.3.4)0.8400.840HypertensionPresent9(8.7)2(7.3.4)0.840Diabetes MellitusPresent4(10.25)3(10)0.743Diabetes MellitusPresent8(89.75)2(90)0.743HypertensionPresent0.7070.666.7)0.701HypertensionPresent0.7070.666.7)0.933Montension20(7)0.666.7)0.9330.933Materian BiotoryPresent0.614.100.00.00.01Materian BiotoryPresent0.614.100.00.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.00.01Materian BiotoryPresent0.8(2)0.010.01Materian BiotoryPresent0.8(2)0.010.01Materian BiotoryPresent0.8(2)0.010.01Materian BiotoryPresent0.8(2)0.010.01Mate	Smoking	Present	12(30)	10(33.3)	0.874
Addiction history Memory Highermetriant Present7(17.9)8(26.6)0.611Hypertension Hypertension Diabetes MellitusPresent10(87.3)2(73.4)0.840Present40(87.3)2(73.4)0.8400.840Diabetes MellitusPresent4(10.25)3(10)0.743Diabetes MellitusPresent6(89.75)27(90)0.641MypertipidemiaPresent9(33.0)0.6430.611MypertipidemiaPresent3(74.70)20(6.7)0.641StrokePresent3(74.70)20(6.7)0.61StrokePresent2(5.1)1(3.33,0)0.931Monto3(74.70)20(96.6)0.0010.01StrokePresent16(4.1)0.00<0.01		Absent	27(70)	20(66.7)	
Absent2k82.1)2(73.4)Image (1)HypertensionPresent1048.7)8(26.6)0.840Masent2(51.3)2(73.4)(1)Diabes MelliusPresent4(10.25)3(10)0.743Masent3(89.75)3(0)0.344HyperlipideniaPresent9(23)0(33.3)0.344HyperlipideniaPresent0(37.1)20(6.7)0.344Masent2(5.1)1(3.33)0.9530.01Stroke HistoryPresent2(5.1)3(3.3)0.953Masent2(94.9)30(0.0)0.0010.01Masent2(82.9)30(100)0.0010.01Masent2(82.9)30(100)0.010.01Masent2(82.9)30(100)0.010.01Masent2(82.9)30(100)0.010.01Masent2(82.9)30(100)0.010.01Masent2(82.9)30(100)0.010.01Masent2(82.9)30(100)0.010.01Masent2(82.9)30(100)1.010.01Masent2(82.9)30(100)1.010.01Masent2(82.9)30(100)1.011.01Masent2(82.9)3.011.011.01Masent2(87.9)3.011.011.01Masent2(97.9)3.011.011.01Masent2(97.9)3.011.011.01Masent2(97.9)3.011.01 <t< td=""><td>Addiction history</td><td>Present</td><td>7(17.9)</td><td>8(26.6)</td><td>0.611</td></t<>	Addiction history	Present	7(17.9)	8(26.6)	0.611
HypertensionPresent19(48.7)8(26.6)0.840Absent20(51.3)2(73.4)7Diabetes MellitusPresent4(10.25)3(10)0.743HyperlipideniaPresent8(58.75)27(90.0)0.344HyperlipideniaPresent9(23)10(33.3)0.344Momeral30(77)20(66.7)0.0010.01Stroke HistoryPresent2(51.1)1(3.33)0.953Mutable angina historyPresent16(41)0(0.0)<0.001		Absent	32(82.1)	22(73.4)	
Aben20(51.3)2(73.4)IDiabetes MellitusPresent4(10.25)3(10)0.743Maent5(89.75)7(90)IHyperlpidemiaPresent9(23)10(33.3)0.341Mosent20(7)20(6.7)IIStroke HistoryPresent2(5.1)0.9530.953Maent3(70)2096.6)IIMasent20(9)2096.6)IIMasent20(9)30(10)IMather20(3)30(10)IIMather20(3)30(10)IIMather20(3)30(10)IIMather20(3)30(10)IIMather20(3)30(10)IIMather20(3)1.0IIMather7(18)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather20(7)IIIMather10(2)IIIMather10(2)IIIMather <td>Hypertension</td> <td>Present</td> <td>19(48.7)</td> <td>8(26.6)</td> <td>0.840</td>	Hypertension	Present	19(48.7)	8(26.6)	0.840
Pisent4(10.25)3(10)0.743HyperlipidemiaFesent3(389.75)2(90)1HyperlipidemiaPresent9(23)10(3.3.3)0.344Mont3(07)0(3.3.3)0.3443Streent2(5.1)1(3.3.3)0.344Streent2(5.1)1(3.3.3)0.34Masent3(94.9)2(96.6)1Masent2(90.6)0.00<0.01		Absent	20(51.3)	22(73.4)	
IdentionAbsent3(89.75)2(90)IdentionHyperlipidemiaPresent9(23)10(3.3)0.344Mont3(77)2(66.7)IdentionStroke HistoryPresent2(5.1)1(3.3)0.953Mont3(94.9)29(96.6)Idention0.00Muscle angina historyPresent3(40.0)3(000.0)0.00Muscle angina historyPresent3(82.0)3(00.0)0.00Muscle angina historyPresent3(82.0)0.000.00Muscle angina historyIdention3(82.0)0.000.00Muscle angina historyIdention3(82.0)0.000.00Muscle angina historyIdention3(80.0)0.000.00Muscle angina historyIdention3(80.0)0.000.00Muscle angina historyIdention3(80.0)0.000.00Muscle angina historyIdention3(80.0)0.000.00Muscle angina historyIdention3(80.0)0.000.00Muscle angina historyIdention3(10.0)1.000.00Muscle angina historyIdention10.201.000.00Muscle angina historyIdention10.201.001.00Muscle angina historyIdentified10.201.001.00Muscle angina historyIdentified10.201.001.00Muscle angina historyIdentifiedIdentified1.001.00Muscle angina history	Diabetes Mellitus	Present	4(10.25)	3(10)	0.743
HyperlipidemiaPresent9(23)10(33.3)0.344Mosent30(77)20(66.7)(1000000000000000000000000000000000000		Absent	35(89.75)	27(90)	
Indext NetworkAbsent30(77)20(66,7)Indext NetworkStroke HistoryPresent3(3,1)0,953Instable angina historyPresent16(41)0(0.0)<0.001	Hyperlipidemia	Present	9(23)	10(33.3)	0.344
Stroke History MemberPresent2(5.1)(1.3.3)0.953Absent37(94.9)29(96.6)Unstable angina history MemberPresent16(41)0.00Mabent23(59)30(10)Killip classification MemberI32(82)Millip classification MemberI32(82)Figetion fraction Member30%7(18) </td <td></td> <td>Absent</td> <td>30(77)</td> <td>20(66.7)</td> <td></td>		Absent	30(77)	20(66.7)	
Absent37(94.9)29(96.6)IUstable angina historyPresent16(41)0(0.0)<0.01	Stroke History	Present	2(5.1)	1(3.33)	0.953
Present16(41)00.0<0.00Absent2(59)0(10)Killip classificationI3(82)T7(8)Spectron fraction30%7(18)Spectron fraction30%7(18)Spectron fraction2057Spectron fractionGrad I2(57)Spectron fractionGrad I2(7)Spectron fractionGrad I1(28)Spectron fractionGrad I1(28)10±24.100.45-Spectron fractionGrad I1(28)10±24.100.45-Spectron fractionSpectron fraction10±24.100.45-Spectron fractionSpectron fraction10±370.45-Spectron fraction15.59±8.4510±37.000.49-Spectron fraction15.59±8.4510±37.000.45-Spectron fraction15.59±8.6710±37.000.45-Spectron fraction15.59±8.6710±37.000.45-Spectron fraction15.59±8.6710±37.000.45-Spectron fraction15.40.6710±37.000.45-Spectro fraction15.59±8.6710±37.000.45-Spectro fraction15.63±7.0015±1.000.45-Spectro fraction10±4.6710±4.57 <t< td=""><td></td><td>Absent</td><td>37(94.9)</td><td>29(96.6)</td><td></td></t<>		Absent	37(94.9)	29(96.6)	
IndexAbsent3(35)3(10)IndexKillip classificationI3(82)Index7(8)Specing fraction7(8)Madde7(8)Madde2(57)Specing fractionGrade I2(7) <t< td=""><td>Unstable angina history</td><td>Present</td><td>16(41)</td><td>0(0.0)</td><td>&lt;0.001</td></t<>	Unstable angina history	Present	16(41)	0(0.0)	<0.001
FilipclassificationI 1 I I I3(82)- - I <td></td> <td>Absent</td> <td>23(59)</td> <td>30(100)</td> <td></td>		Absent	23(59)	30(100)	
ImageImageImageImageImageImage50%7(18)30.40%7(18)40.50%2(57)50%3(7)End diastolicGrade I28(7)Lef ventricular functionGrade I11(28)FBS (mg/d)Torade I10.12±25.6610±24.10.345FDL-C (mg/d)V162.8±38.7010±34.670.061LDL-C (mg/d)V96.7±35.13010±370.084FDL-C (mg/d)V155.9±84.67416±87.470.093FG (mg/d)V95.0±8.67416±87.470.093FUNV52.59±84.67416±87.470.994FUNV50.59±84.67416±87.470.433FunglobinV9.94±0.2880.85±0.30.833HematocritV10.424.500.5320.532Base LineIGF19.12±0.1124±500.12FUE 010.9±110124±500.120.12	Killip classification	Ι	32(82)	-	-
Fjection fraction performance<30%7(18)3040%7(18) <td></td> <td>II</td> <td>7(18)</td> <td>-</td> <td></td>		II	7(18)	-	
90-40%7(18)40-50%22(57)>50%3(7)End diastolicGrade I28(72)Left ventricular functionGrade I11(28)FBS (mg/d)-10.12±25.66110±24.10.345TC (mg/d)-162.88±38.70165±40.670.061LDL-C (mg/d)-96.77±35.130100±370.084HDL-C (mg/d)-152.59±84.674160±87.470.099Grade II52.59±84.674160±87.470.099BUN-7.50±8.8825±7.980.455Creatinine0.994±0.2880.85±0.30.833Hemoglobin12.63±1.7913.5±1.940.433Hematocrit9.194±4.6742±4.50.532Base LineHGF19.3±21011294±5620.1	Ejection fraction	<30%	7(18)	-	-
$40.50\%$ $22(57)$ $  50\%$ $3(7)$ $ -$ End diastolic         Grade I $28(72)$ $ -$ Left ventricular function         Grade I $1(28)$ $ -$ FBS (mg/dl)         Grade II $11(28)$ $  -$ FDS (mg/dl) $ 1012\pm25.66$ $10\pm24.1$ $0.345$ TC (mg/dl) $ 162.88\pm38.70$ $165\pm40.67$ $0.061$ LDL-C (mg/dl) $ 96.77\pm35.130$ $100\pm37$ $0.084$ HDL-C (mg/dl) $ 152.59\pm84.674$ $160\pm87.47$ $0.099$ SUN $ 7.50\pm8.88$ $25\pm7.98$ $0.435$ Greatinine $0.994\pm0.288$ $0.85\pm0.3$ $0.833$ Hemoglobin $12.63\pm1.79$ $13.5\pm1.94$ $0.433$ Hematocrit $9.194\pm4.67$ $42\pm4.5$ $0.532$ Base Line         HGF $91.93\pm110$ $12.7$ $0.27$		30-40%	7(18)	-	
>50%3(7)End diastolicGrade I28(72)Left ventricular functionGrade II11(28)FBS (mg/dl)120.12±25.66110±24.10.345TC (mg/dl)162.88±38.70165±40.670.061LDL-C (mg/dl)96.77±35.130100±370.084HDL-C (mg/dl)152.59±84.674100±37.40.093TG (mg/dl)152.59±84.674160±87.470.099BUN7.50±8.8825±7.980.455Greatinine0.994±0.2880.85±0.30.833Hemoglobin12.63±1.7913.5±1.940.433Hematocrit91.94±4.6742±4.50.532Base LineHGF1913±21011294±5620.1-TH ca20.59±11017±70.27		40-50%	22(57)	-	
End diastolicGrade I28(72)Left ventricular functionGrade II11(28)<		>50%	3(7)	-	
Left ventricular function         Grade II         11(28)         -         Internation         Internation           FBS (mg/dl) $-$ 10±24.1         0.345           TC (mg/dl)         162.88±38.70         165±40.67         0.061           LDL-C (mg/dl)         96.77±35.130         100±37         0.084           HDL-C (mg/dl) $-$ 152.59±84.674         100±87.47         0.099           BUN         152.59±84.674         160±87.47         0.099         0.099           Greatinine $-$ 57.59±84.674         100±87.47         0.455           BUN $-$ 57.59±84.674         100±87.47         0.455           Greatinine $-$ 0.994±0.288         0.85±0.30         0.453           Hemoglobin $-$ 12.63±1.79         13.5±1.94         0.433           Hematocrit $91.94\pm4.67$ 42±4.5         0.532           Base Line         HGF         1913±2101         129±562         0.1	End diastolic	Grade I	28(72)	-	-
FBS (mg/dl)120.12±25.66110±24.10.345TC (mg/dl) $62.88\pm38.70$ $65\pm40.67$ $0.061$ LDL-C (mg/dl) $96.77\pm35.130$ $100\pm37$ $0.084$ HDL-C (mg/dl) $41.55\pm8.25$ $43\pm9.54$ $0.093$ TG (mg/dl) $152.59\pm84.674$ $60\pm87.477$ $0.099$ BUN $7.50\pm8.88$ $25\pm7.98$ $0.455$ Creatinine $0.994\pm0.288$ $0.85\pm0.3$ $0.833$ Hemoglobin $12.63\pm1.79$ $13.5\pm1.94$ $0.433$ Hematocrit $9.194\pm4.67$ $42\pm4.5$ $0.532$ Base LineHGF $191\pm2101$ $129\pm562$ $0.17$	Left ventricular function	Grade II	11(28)	-	
TC (mg/dl)162.88 $\pm$ 38.70165 $\pm$ 40.670.061LDL-C (mg/dl)96.77 $\pm$ 35.130100 $\pm$ 370.084HDL-C (mg/dl)41.55 $\pm$ 8.2543 $\pm$ 9.540.093TG (mg/dl)152.59 $\pm$ 84.674160 $\pm$ 87.470.099BUN27.50 $\pm$ 8.8825 $\pm$ 7.980.455Creatinine0.994 $\pm$ 0.2880.85 $\pm$ 0.30.833Hemoglobin12.63 $\pm$ 1.7913.5 $\pm$ 1.940.433Hematocrit99.194 $\pm$ 4.6742 $\pm$ 4.50.532Base LineIGF1913 $\pm$ 21011294 $\pm$ 5620.1	FBS (mg/dl)		120.12±25.66	110±24.1	0.345
LDL-C (mg/dl)       96.77 $\pm$ 35.130       100 $\pm$ 37       0.084         HDL-C (mg/dl)       41.55 $\pm$ 8.25       43 $\pm$ 9.54       0.093         TG (mg/dl)       152.59 $\pm$ 84.674       160 $\pm$ 87.47       0.099         BUN       27.50 $\pm$ 8.88       25 $\pm$ 7.98       0.455         Creatinine       0.994 $\pm$ 0.288       0.85 $\pm$ 0.3       0.833         Hemoglobin       12.63 $\pm$ 1.79       13.5 $\pm$ 1.94       0.433         Hematocrit       39.194 $\pm$ 4.67       42 $\pm$ 4.5       0.532         Base Line       HGF       191 $\pm$ 2101       129 $\pm$ 562       0.1	TC (mg/dl)		$162.88 \pm 38.70$	$165 \pm 40.67$	0.061
HDL-C (mg/dl) $41.55\pm8.25$ $43\pm9.54$ $0.093$ TG (mg/dl) $152.59\pm84.674$ $160\pm87.47$ $0.099$ BUN $27.50\pm8.88$ $25\pm7.98$ $0.455$ Creatinine $0.994\pm0.288$ $0.85\pm0.3$ $0.833$ Hemoglobin $12.63\pm1.79$ $13.5\pm1.94$ $0.433$ Hematocrit $9.194\pm4.67$ $42\pm4.5$ $0.532$ Base Line       HGF $191\pm2101$ $129\pm562$ $0.1$	LDL-C (mg/dl)		96.77±35.130	$100 \pm 37$	0.084
TG (mg/dl)       152.59±84.674       160±87.47       0.099         BUN       27.50±8.88       25±7.98       0.455         Creatinine       0.994±0.288       0.85±0.3       0.833         Hemoglobin       12.63±1.79       13.5±1.94       0.433         Hematocrit       39.194±4.67       42±4.5       0.532         Base Line       HGF       1913±2101       1294±562       0.1	HDL-C (mg/dl)		41.55±8.25	43±9.54	0.093
BUN         27.50±8.88         25±7.98         0.455           Creatinine         0.994±0.288         0.85±0.3         0.833           Hemoglobin         12.63±1.79         13.5±1.94         0.433           Hematocrit         39.194±4.67         42±4.5         0.532           Base Line         HGF         1913±2101         1294±562         0.1	TG (mg/dl)		152.59±84.674	$160 \pm 87.47$	0.099
Creatinine         0.994±0.288         0.85±0.3         0.833           Hemoglobin         12.63±1.79         13.5±1.94         0.433           Hematocrit         39.194±4.67         42±4.5         0.532           Base Line         HGF         1913±2101         1294±562         0.1	BUN		$27.50 \pm 8.88$	$25 \pm 7.98$	0.455
Hemoglobin         12.63±1.79         13.5±1.94         0.433           Hematocrit         39.194±4.67         42±4.5         0.532           Base Line         HGF         1913±2101         1294±562         0.1           TNE c         39.59±110         17±7         0.37	Creatinine		$0.994 \pm 0.288$	$0.85 \pm 0.3$	0.833
Hematocrit         39.194±4.67         42±4.5         0.532           Base Line         HGF         1913±2101         1294±562         0.1           TNE q         29.59±110         17±7         0.27	Hemoglobin		12.63±1.79	13.5±1.94	0.433
Base Line         HGF         1913±2101         1294±562         0.1           TNF q         29 59±110         17±7         0.27	Hematocrit		39.194±4.67	42±4.5	0.532
TNE $\alpha$ 20 50+110 17+7 0.27	Base Line	HGF	1913±2101	1294±562	0.1
1NF-u 57.37±117 1/±/ 0.2/		TNF-a	39.59±119	17±7	0.27
IL-6 132.26±86.41 52±13 0.001		IL-6	132.26±86.41	52±13	0.001

Data in this table shown as: Mean $\pm$ SD and percentage in parentheses.

<sup>a</sup> FBS: Fasting blood sugar <sup>b</sup> TC: total cholesterol

° LDL-C: Low density lipoprotein- cholesterol

<sup>d</sup> HDL-C: High density lipoprotein- cholesterol

<sup>e</sup> TG: triglyceride

Lead	Abnormal Findings	No.(%)
Lateral leads	Present	14(36)
	Absent	25(64)
Anterior leads	Present	18(46)
	Absent	21(54)
Inferior leads	Present	30(77)
	Absent	9(23)
Right lead	Present	8(20)
	Absent	31(80)
Posterior lead	Present	7(18)
	Absent	32(82)

Table 2- electrocardiogram abnormal findings

Table 3- Cytokine assay in Case group during hospital stay<sup>a</sup>

	Base line	3rd days after AMI	7th days after AMI	Р	P <sub>1</sub> <sup>c</sup>	$\mathbf{P}_2^{\ d}$
$\mathrm{HGF}_{(\mathrm{pg/mL})}$	1360(1225-1601)	1810(1310-2516)	1913(1565-4367)	0.006	0.006	0.019
TNF-a (pg/mL)	3.2(2.9-3.6)	3.3(3-3.7)	3.3(3.1-3.8)	0.012	0.008	0.006
IL-6 <sub>(pg/mL)</sub>	102(86-142)	167(145-408)	203(162-590)	< 0.001	< 0.001	< 0.001

<sup>a</sup> Data shown as Median (Interquartile range)

<sup>b</sup> P<sub>0</sub> is P value of comparing between base line via 3<sup>rd</sup> days after AMI.

<sup>c</sup> P<sub>1</sub> is P value of comparing between base line via 7<sup>th</sup> days after AMI.

 $^{\rm d}$   $\rm P_{2}$  is P value of comparing between 3<sup>rd</sup> days via 7<sup>th</sup> days after AMI.

#### **Discussion**

The main findings of this study are that (1) IL-6 increases in early phase after AMI and that (2) serial elevation in serum levels of IL-6, TNF- $\alpha$  and HGF occurs after AMI.

It had been proved previously that thrombus formation induces the HGF circulating and it is increasing after AMI.<sup>21</sup> Also HGF serum level is higher in angina pectoris and old myocardial infarction.<sup>22</sup> Soeki et al. showed that HGF levels in patients with AMI were higher than control values at the time of admission. Also, levels of HGF on day 7 after AMI were higher than baseline levels<sup>18</sup>. In the present study, although difference between baseline HGF in case group and control group was not significant, HGF levels of case group in day 3 was higher than baseline and in day 7 was higher than baseline and 3rd day. Serial increased levels of HGF over time, have not been reported previously.

Cytokine IL-6 is the major procoagulant that is secreted by numerous cells such as monocytes, lymphocytes, fibroblasts, endothelial cells and smooth muscle.<sup>23</sup> Puhakka et al. found that IL-6 has increased immediately and transiently after AMI.<sup>24</sup> In a case-control study with 1179 surviving AMI cases and 1528 healthy controls, it was proved that in men, MI risk was higher with increasing IL-6 levels.<sup>25</sup>

Increased IL-6 in the first 48 hours after ACS is associated with prognosis of future cardiovascular events.<sup>23</sup> In addition, IL-6 in the patients with refractory unstable angina are higher than those with stable angina.<sup>26</sup> A study that was conducted on 38 patients with stroke showed that IL-6 levels are increased in stroke with mechanisms of atherosclerosis plaque rapture.<sup>27</sup> We found same result in our study; IL-6 was higher in case group than controls at the admission time. It also increased serially on 3rd day and 7th day after admission.

 $TNF\text{-}\alpha$  can be produced by many cell types such as macrophage cells, lymphoid cells, mast cells, endothelial cells,

cardiac myocytes and adipose tissue. It is known as a regulator of inflammatory cells, and as a pyrogenic agent. TNF- $\alpha$  is involved in almost all aspects of the inflammatory process of atherosclerosis.<sup>28</sup> High levels of TNF- $\alpha$  in the patients after AMI is an independent risk factor in cardiovascular events occuring again.<sup>28</sup> It was shown before that TNF- $\alpha$  increase significantly on admission and 24 hours post admission in AMI patients comparing to control group.<sup>29</sup> Although high levels of TNF- $\alpha$  on admission time were not confirmed in our study, serial increase of this cytokine over time was observed.

## Conclusion

We have reported increased levels of IL-6, TNF-a and HGF during AMI with ST-segment elevation patients. At the admission time, the IL-6 levels were significantly higher than the control group. So, besides the clinical signs and symptoms of AMI, measuring IL-6 may be helpful for diagnosis of this disease. It seems that further studies are needed to determine sensitivity and specificity in larger number of patients.

### **Conflict of Interest Statement**

The authors indicate no potential conflicts of interest.

#### **Ethical approval**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

#### Funding

This study was supported by Mashhad University of Medical Sciences.

#### References

1. Chen C, Lei W, Chen W, et al. Serum TGF-beta1 and

SMAD3 levels are closely associated with coronary artery disease. BMC cardiovascular disorders. 2014;14:18. https://doi.org/10.1186/1471-2261-14-18

- 2. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics--2014 Update: A Report From the American Heart Association. Circulation. 2013.
- 3. Biswas S, Ghoshal PK, Mandal N. Synergistic effect of anti and pro-inflammatory cytokine genes and their promoter polymorphism with ST-elevation of myocardial infarction. Gene. 2014;544(2):145-51. https://doi.org/10.1016/j.gene.2014.04.065
- Anderson DR, Poterucha JT, Mikuls TR, et al. IL-6 and its 4. receptors in coronary artery disease and acute myocardial infarction. Cytokine. 2013;62(3):395-400. https://doi.org/10.1016/j.cyto.2013.03.020
- Mendis S, Puska P, Norrving B, Organization WH, 5. Federation WH, Organization WS. Global Atlas on Cardiovascular Disease Prevention and Control: World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011.
- 6. Rajappa M, Sen S, Sharma A. Role of pro-/anti-inflammatory cytokines and their correlation with established risk factors in South Indians with coronary artery disease. Angiology. 2009;60(4):419-26.

https://doi.org/10.1177/0003319708321101

Antonicelli R, Olivieri F, Bonafe M, et al. The interleukin-6 7. -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. International journal of cardiology. 2005;103(3):266-71.

https://doi.org/10.1016/j.ijcard.2004.08.064

Antonicelli R, Olivieri F, Cavallone L, et al. Tumor necrosis 8. factor-alpha gene -308G>A polymorphism is associated with ST-elevation myocardial infarction and with high plasma levels of biochemical ischemia markers. Coronary artery disease. 2005;16(8):489-93.

https://doi.org/10.1097/00019501-200512000-00006

- 9 Ohtsuka T, Hamada M, Inoue K, et al. Relation of circulating interleukin-6 to left ventricular remodeling in patients with reperfused anterior myocardial infarction. Clin Cardiol. 2004;27(7):417-20. https://doi.org/10.1002/clc.4960270712
- Kanikowska D, Pyda M, Korybalska K, et al. Age-related 10. limitations of interleukin-6 in predicting early mortality in acute ST-elevation myocardial infarction. Immunity & ageing : I & A. 2014;11(1):23. https://doi.org/10.1186/s12979-014-0023-7
- Tousoulis D, Antoniades C, Koumallos N, et al. Pro-11. inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine & growth factor reviews. 2006;17(4):225-33. https://doi.org/10.1016/j.cytogfr.2006.04.003
- Pudil R, Pidrman V, Krejsek J, et al. Cytokines and adhesion 12. molecules in the course of acute myocardial infarction. Clin Chim Acta. 1999;280(1-2):127-34. https://doi.org/10.1016/S0009-8981(98)00179-X
- 13. Martins TB, Anderson JL, Muhlestein JB, et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. American journal of clinical pathology. 2006;125(6):906-13. https://doi.org/10.1309/Q3E6KF0QD3U3YL6T
- Jin H, Wyss JM, Yang R, et al. The therapeutic potential of 14. hepatocyte growth factor for myocardial infarction and heart failure. Current pharmaceutical design. 2004;10(20):2525-33. https://doi.org/10.2174/1381612043383863
- 15. Konopka A, Janas J, Piotrowski W, et al. Hepatocyte growth

factor - the earliest marker of myocardial injury in STsegment elevation myocardial infarction. Kardiologia polska. 2013;71(8):827-31. https://doi.org/10.5603/KP.2013.0194

- 16. Matsumori A, Furukawa Y, Hashimoto T, et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochemical and biophysical research communications. 1996;221(2):391-5. https://doi.org/10.1006/bbrc.1996.0606
- 17. Zhu Y, Hojo Y, Ikeda U, et al. Production of hepatocyte growth factor during acute myocardial infarction. Heart (British Cardiac Society). 2000;83(4):450-5. https://doi.org/10.1136/heart.83.4.450
- Soeki T, Tamura Y, Shinohara H, et al. Serial changes in 18. serum VEGF and HGF in patients with acute myocardial infarction. Cardiology. 2000;93(3):168-74. https://doi.org/10.1159/000007022
- Killip T, 3rd, Kimball JT. Treatment of myocardial infarction 19. in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20(4):457-64. https://doi.org/10.1016/0002-9149(67)90023-9
- 20. Kazemi-Bajestani SM, Ghayour-Mobarhan M, Ebrahimi M, et al. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease. Clin Lab. 2007;53(1-2):49-56. https://doi.org/10.1016/S1567-5688(08)70910-3
- 21. Brown LF, Yeo KT, Berse B, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992;176(5):1375-9. https://doi.org/10.1084/jem.176.5.1375
- Soeki T, Tamura Y, Shinohara H, et al. Role of circulating 22. vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels. 2000;15(3):105-11. https://doi.org/10.1007/PL00007263
- 23. Mouco OM, Nicolau JC, Souza Tda R, et al. [Inflammatory markers of atherosclerotic plaque stabilization after acute coronary event--temporal trends]. Arq Bras Cardiol. 2006;87(1):28-36.

https://doi.org/10.1590/S0066-782X2006001400005 24. Puhakka M, Magga J, Hietakorpi S, et al. Interleukin-6 and tumor necrosis factor alpha in relation to myocardial infarct size and collagen formation. J Card Fail. 2003;9(4):325-32.

- https://doi.org/10.1054/jcaf.2003.38 25. Bennet AM, Prince JA, Fei GZ, et al. Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction. Atherosclerosis. 2003;171(2):359-67. https://doi.org/10.1016/j.atherosclerosis.2003.08.029
- 26. Hojo Y, Ikeda U, Takahashi M, et al. Increased levels of monocyte-related cytokines in patients with unstable angina. Atherosclerosis. 2002;161(2):403-8. https://doi.org/10.1016/S0021-9150(01)00636-0
- 27. Kim HM, Shin HY, Jeong HJ, et al. Reduced IL-2 but elevated IL-4, IL-6, and IgE serum levels in patients with cerebral infarction during the acute stage. J Mol Neurosci. 2000;14(3):191-6. https://doi.org/10.1385/JMN:14:3:191
- 28. Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. Atherosclerosis as an inflammatory disease. Curr Pharm Des. 2012;18(28):4266-88. https://doi.org/10.2174/138161212802481237, https://doi.org/10.2174/138161212802481246
- 29. Fahim MR, Halim SM, Kamel I. Tumor necrosis factor alpha in patients with acute myocardial infarction. The Egyptian journal of immunology / Egyptian Association of Immunologists. 2004;11(1):31-7.